Keytruda, Merck's flagship oncology drug, drives significant revenue growth, with a solid market position and patent protection ensuring continued growth. Merck is the second largest player in the ...

Merck's Q3 sales reached $16.7 billion, a 4% YoY increase, beating the $16.5 billion consensus estimate. Merck reported a decline of 11% in sales of Gardasil to $2.31 billion, a vaccine that ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. RAHWAY, N.J. – While the Dow Jones Industrial Average has reached all-time highs recently, one of its ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition and likely see sales slide noticeably. There aren't any obvious ...

(RTTNews) - Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the company's investigational prophylactic monoclonal ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the consensus of $16.47 billion. Merck reported a decline of 11% in sales of ...